NCT04893525View on ClinicalTrials.gov

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

658

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Opioid-use Disorder
Interventions
DRUG

Buprenorphine/naloxone

Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.

Trial Locations (6)

T2N2T9

RECRUITING

Foothills Medical Centre, Calgary

T5A 5E4

RECRUITING

Northeast Community Health Centre, Edmonton

T5H 3V9

NOT_YET_RECRUITING

Royal Alexandra Hospital, Edmonton

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

V6T2B5

RECRUITING

University of British Columbia Hospital, Vancouver

V6Z 1Y6

RECRUITING

St. Paul's Hospital, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER